Format
Sort by
Items per page

Send to

Choose Destination

Best matches for O’Brien CP[au]:

Molecular Genetics and New Medication Strategies for Opioid Addiction. Hurd YL et al. Am J Psychiatry. (2018)

DSM-5 criteria for substance use disorders: recommendations and rationale. Hasin DS et al. Am J Psychiatry. (2013)

Internet Gaming Disorder in the DSM-5. Petry NM et al. Curr Psychiatry Rep. (2015)

Search results

Items: 1 to 50 of 460

1.

Molecular tuning of CO2-to-ethylene conversion.

Li F, Thevenon A, Rosas-Hernández A, Wang Z, Li Y, Gabardo CM, Ozden A, Dinh CT, Li J, Wang Y, Edwards JP, Xu Y, McCallum C, Tao L, Liang ZQ, Luo M, Wang X, Li H, O'Brien CP, Tan CS, Nam DH, Quintero-Bermudez R, Zhuang TT, Li YC, Han Z, Britt RD, Sinton D, Agapie T, Peters JC, Sargent EH.

Nature. 2020 Jan;577(7791):509-513. doi: 10.1038/s41586-019-1782-2. Epub 2019 Nov 20.

PMID:
31747679
2.

Dopant-tuned stabilization of intermediates promotes electrosynthesis of valuable C3 products.

Zhuang TT, Nam DH, Wang Z, Li HH, Gabardo CM, Li Y, Liang ZQ, Li J, Liu XJ, Chen B, Leow WR, Wu R, Wang X, Li F, Lum Y, Wicks J, O'Brien CP, Peng T, Ip AH, Sham TK, Yu SH, Sinton D, Sargent EH.

Nat Commun. 2019 Oct 22;10(1):4807. doi: 10.1038/s41467-019-12788-0.

3.

Development of the Revised Opioid Risk Tool to Predict Opioid Use Disorder in Patients with Chronic Nonmalignant Pain.

Cheatle MD, Compton PA, Dhingra L, Wasser TE, O'Brien CP.

J Pain. 2019 Jul;20(7):842-851. doi: 10.1016/j.jpain.2019.01.011. Epub 2019 Jan 26.

PMID:
30690168
4.

Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual.

Soares WE 3rd, Wilson D, Gordon MS, Lee JD, Nunes EV, O'Brien CP, Shroff M, Friedmann PD.

Drug Alcohol Depend. 2019 Jan 1;194:482-486. doi: 10.1016/j.drugalcdep.2018.10.035. Epub 2018 Dec 3.

5.

Molecular Genetics and New Medication Strategies for Opioid Addiction.

Hurd YL, O'Brien CP.

Am J Psychiatry. 2018 Oct 1;175(10):935-942. doi: 10.1176/appi.ajp.2018.18030352. Epub 2018 Aug 2. Review.

6.

Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.

Shi Z, Wang AL, Jagannathan K, Fairchild VP, O'Brien CP, Childress AR, Langleben DD.

J Psychiatry Neurosci. 2018 Jul;43(4):254-261.

7.

Response to Dr. McAuliffe.

Cheatle MD, Gallagher RM, O'Brien CP.

Pain Med. 2018 May 1;19(5):1102-1103. doi: 10.1093/pm/pny042. No abstract available.

PMID:
29546331
8.

Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.

Shi Z, Wang AL, Jagannathan K, Fairchild VP, O'Brien CP, Childress AR, Langleben DD.

J Psychiatry Neurosci. 2018 Feb 23;43(3):170036. doi: 10.1503/jpn.170036. [Epub ahead of print]

9.

Personal Control Over Decisions to Participate in Research by Persons With Histories of Both Substance Use Disorders and Criminal Justice Supervision.

Chen DT, Ko TM, Allen AA, Bonnie RJ, Suratt CE, Appelbaum PS, Nunes EV, Friedmann PD, Lee JD, Gordon MS, McDonald R, Wilson D, Boney TY, Murphy SM, O'Brien CP.

J Empir Res Hum Res Ethics. 2018 Apr;13(2):160-172. doi: 10.1177/1556264618755243. Epub 2018 Feb 20.

10.

Evolution of surface catalytic sites on thermochemically-tuned gold-palladium nanoalloys.

Kareem H, Shan S, Lin F, Li J, Wu Z, Prasai B, O'Brien CP, Lee IC, Tran DT, Yang L, Mott D, Luo J, Petkov V, Zhong CJ.

Nanoscale. 2018 Feb 22;10(8):3849-3862. doi: 10.1039/c7nr08748a.

PMID:
29417115
11.

Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.

Frawley T, O'Brien CP, Conneally E, Vandenberghe E, Percy M, Langabeer SE, Haslam K.

Genet Test Mol Biomarkers. 2018 Feb;22(2):98-103. doi: 10.1089/gtmb.2017.0203. Epub 2018 Jan 11.

PMID:
29323541
12.

Effectiveness, Implementation and Real-World Experience with Extended-Release Naltrexone (XR-NTX): A Special Issue of JSAT.

Friedmann PD, Dunn KE, Nunes EV, O'Brien CP.

J Subst Abuse Treat. 2018 Feb;85:31-33. doi: 10.1016/j.jsat.2017.11.008. Epub 2017 Nov 22. No abstract available.

PMID:
29273249
13.

Assessing informed consent in an opioid relapse prevention study with adults under current or recent criminal justice supervision.

Allen AA, Chen DT, Bonnie RJ, Ko TM, Suratt CE, Lee JD, Friedmann PD, Gordon M, McDonald R, Murphy SM, Boney TY, Nunes EV, O'Brien CP.

J Subst Abuse Treat. 2017 Oct;81:66-72. doi: 10.1016/j.jsat.2017.07.015. Epub 2017 Aug 1.

14.

Catalysis beyond frontier molecular orbitals: Selectivity in partial hydrogenation of multi-unsaturated hydrocarbons on metal catalysts.

Liu W, Jiang Y, Dostert KH, O'Brien CP, Riedel W, Savara A, Schauermann S, Tkatchenko A.

Sci Adv. 2017 Jul 26;3(7):e1700939. doi: 10.1126/sciadv.1700939. eCollection 2017 Jul.

15.

Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual.

Soares WE 3rd, Wilson D, Rathlev N, Lee JD, Gordon M, Nunes EV, O'Brien CP, Friedmann PD.

J Subst Abuse Treat. 2018 Feb;85:66-69. doi: 10.1016/j.jsat.2017.05.009. Epub 2017 May 12.

PMID:
28576389
16.

Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone.

Nunes EV, Gordon M, Friedmann PD, Fishman MJ, Lee JD, Chen DT, Hu MC, Boney TY, Wilson D, O'Brien CP.

J Subst Abuse Treat. 2018 Feb;85:49-55. doi: 10.1016/j.jsat.2017.04.016. Epub 2017 Apr 23.

17.

Low Risk of Producing an Opioid Use Disorder in Primary Care by Prescribing Opioids to Prescreened Patients with Chronic Noncancer Pain.

Cheatle MD, Gallagher RM, O'Brien CP.

Pain Med. 2018 Apr 1;19(4):764-773. doi: 10.1093/pm/pnx032.

18.

Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder.

Murphy SM, Polsky D, Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Bonnie RJ, Gordon M, Chen DT, Boney TY, O'Brien CP.

Addiction. 2017 Aug;112(8):1440-1450. doi: 10.1111/add.13807. Epub 2017 Apr 12.

19.

Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?

Friedmann PD, Wilson D, Nunes EV, Hoskinson R Jr, Lee JD, Gordon M, Murphy SM, Bonnie RJ, Chen DT, Boney TY, O'Brien CP.

J Subst Abuse Treat. 2018 Feb;85:61-65. doi: 10.1016/j.jsat.2017.01.018. Epub 2017 Feb 22.

20.

Image-guided intrathecal baclofen pump catheter implantation: a technical note and case series.

Robinson S, Robertson FC, Dasenbrock HH, O'Brien CP, Berde C, Padua H.

J Neurosurg Spine. 2017 May;26(5):621-627. doi: 10.3171/2016.8.SPINE16263. Epub 2017 Feb 3.

PMID:
28156208
21.

Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment.

Gordon MS, Vocci FJ, Fitzgerald TT, O'Grady KE, O'Brien CP.

Contemp Clin Trials. 2017 Feb;53:130-136. doi: 10.1016/j.cct.2016.12.015. Epub 2016 Dec 20.

22.

Selective Hydrogenation of Acrolein Over Pd Model Catalysts: Temperature and Particle-Size Effects.

O'Brien CP, Dostert KH, Schauermann S, Freund HJ.

Chemistry. 2016 Oct 24;22(44):15856-15863. doi: 10.1002/chem.201602021. Epub 2016 Sep 13.

PMID:
27621113
23.

Emotional, physical and sexual abuse are associated with a heightened limbic response to cocaine cues.

Regier PS, Monge ZA, Franklin TR, Wetherill RR, Teitelman A, Jagannathan K, Suh JJ, Wang Z, Young KA, Gawrysiak M, Langleben DD, Kampman KM, O'Brien CP, Childress AR.

Addict Biol. 2017 Nov;22(6):1768-1777. doi: 10.1111/adb.12445. Epub 2016 Sep 22.

24.

Adsorption of acrolein, propanal, and allyl alcohol on Pd(111): a combined infrared reflection-absorption spectroscopy and temperature programmed desorption study.

Dostert KH, O'Brien CP, Mirabella F, Ivars-Barceló F, Schauermann S.

Phys Chem Chem Phys. 2016 May 18;18(20):13960-73. doi: 10.1039/c6cp00877a.

25.

Twitter at the 2014 and 2015 Annual Meetings of the American Academy of Ophthalmology.

Christiansen SM, Oetting TA, Herz NL, Law JC, O'Brien CP, Patel PS, Patel R, Pettey JH, Shiba DR, Sun G, Fountain T.

Ophthalmology. 2016 Aug;123(8):1835-1837. doi: 10.1016/j.ophtha.2016.03.012. Epub 2016 Apr 7. No abstract available.

PMID:
27067923
26.

Supports and modified nano-particles for designing model catalysts.

O'Brien CP, Dostert KH, Hollerer M, Stiehler C, Calaza F, Schauermann S, Shaikhutdinov S, Sterrer M, Freund HJ.

Faraday Discuss. 2016 Jul 4;188:309-21. doi: 10.1039/c5fd00143a.

PMID:
27064816
27.

Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.

Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA Jr, Wilson D, McDonald R, Rotrosen J, Gourevitch MN, Gordon M, Fishman M, Chen DT, Bonnie RJ, Cornish JW, Murphy SM, O'Brien CP.

N Engl J Med. 2016 Mar 31;374(13):1232-42. doi: 10.1056/NEJMoa1505409.

28.

Griffiths et al.'s comments on the international consensus statement of internet gaming disorder: furthering consensus or hindering progress?

Petry NM, Rehbein F, Gentile DA, Lemmens JS, Rumpf HJ, Mößle T, Bischof G, Tao R, Fung DS, Borges G, Auriacombe M, González-Ibáñez A, Tam P, O'Brien CP.

Addiction. 2016 Jan;111(1):175-8. doi: 10.1111/add.13189. No abstract available.

PMID:
26669531
29.

Bioinformatic Analysis of Antigenic Proteins in Celiac Disease.

O'Brien CP.

Methods Mol Biol. 2015;1326:193-201. doi: 10.1007/978-1-4939-2839-2_16.

PMID:
26498622
30.

Spectators Control Selectivity in Surface Chemistry: Acrolein Partial Hydrogenation Over Pd.

Dostert KH, O'Brien CP, Ivars-Barceló F, Schauermann S, Freund HJ.

J Am Chem Soc. 2015 Oct 28;137(42):13496-502. doi: 10.1021/jacs.5b04363. Epub 2015 Oct 20.

31.

Water Interaction with Iron Oxides.

Dementyev P, Dostert KH, Ivars-Barceló F, O'Brien CP, Mirabella F, Schauermann S, Li X, Paier J, Sauer J, Freund HJ.

Angew Chem Int Ed Engl. 2015 Nov 16;54(47):13942-6. doi: 10.1002/anie.201506439. Epub 2015 Oct 12.

PMID:
26457889
32.

A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence.

Kampman KM, Lynch KG, Pettinati HM, Spratt K, Wierzbicki MR, Dackis C, O'Brien CP.

Drug Alcohol Depend. 2015 Oct 1;155:105-10. doi: 10.1016/j.drugalcdep.2015.08.005. Epub 2015 Aug 14.

33.

Internet Gaming Disorder in the DSM-5.

Petry NM, Rehbein F, Ko CH, O'Brien CP.

Curr Psychiatry Rep. 2015 Sep;17(9):72. doi: 10.1007/s11920-015-0610-0. Review.

PMID:
26216590
34.

Interaction of Isophorone with Pd(111): A Combination of Infrared Reflection-Absorption Spectroscopy, Near-Edge X-ray Absorption Fine Structure, and Density Functional Theory Studies.

Dostert KH, O'Brien CP, Riedel W, Savara A, Liu W, Oehzelt M, Tkatchenko A, Schauermann S.

J Phys Chem C Nanomater Interfaces. 2014 Dec 4;118(48):27833-27842. Epub 2014 Nov 21.

35.

Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence.

Wang AL, Elman I, Lowen SB, Blady SJ, Lynch KG, Hyatt JM, O'Brien CP, Langleben DD.

Transl Psychiatry. 2015 Mar 17;5:e531. doi: 10.1038/tp.2015.20.

36.

Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.

Oslin DW, Leong SH, Lynch KG, Berrettini W, O'Brien CP, Gordon AJ, Rukstalis M.

JAMA Psychiatry. 2015 May;72(5):430-7. doi: 10.1001/jamapsychiatry.2014.3053.

PMID:
25760804
37.

High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.

van den Hurk K, Balint B, Toomey S, O'Leary PC, Unwin L, Sheahan K, McDermott EW, Murphy I, van den Oord JJ, Rafferty M, FitzGerald DM, Moran J, Cummins R, MacEneaney O, Kay EW, O'Brien CP, Finn SP, Heffron CC, Murphy M, Yela R, Power DG, Regan PJ, McDermott CM, O'Keeffe A, Orosz Z, Donnellan PP, Crown JP, Hennessy BT, Gallagher WM.

Melanoma Res. 2015 Jun;25(3):189-99. doi: 10.1097/CMR.0000000000000149.

PMID:
25746038
38.

Limitations of the use of the MP-RAGE to identify neural changes in the brain: recent cigarette smoking alters gray matter indices in the striatum.

Franklin TR, Wetherill RR, Jagannathan K, Hager N, O'Brien CP, Childress AR.

Front Hum Neurosci. 2015 Jan 28;8:1052. doi: 10.3389/fnhum.2014.01052. eCollection 2014. No abstract available.

39.

Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial.

Lee JD, Friedmann PD, Boney TY, Hoskinson RA Jr, McDonald R, Gordon M, Fishman M, Chen DT, Bonnie RJ, Kinlock TW, Nunes EV, Cornish JW, O'Brien CP.

Contemp Clin Trials. 2015 Mar;41:110-7. doi: 10.1016/j.cct.2015.01.005. Epub 2015 Jan 17.

40.

Brief report: "spiders-No, puppies-Go", introducing a novel Go NoGo task tested in inner city adolescents at risk for poor impulse control.

Goldman M, Ehrman RN, Suh JJ, Hurt H, Marquez K, Franklin TR, O'Brien CP, Childress AR.

J Adolesc. 2015 Jan;38:45-8. doi: 10.1016/j.adolescence.2014.10.007. Epub 2014 Nov 24. No abstract available.

41.

Interview with Eddy Award Winner Charles O'Brien, MD, PhD.

O'Brien CP, Denis C.

Drug Alcohol Depend. 2014 Oct 1;143:281-2. No abstract available.

PMID:
25343165
42.

A pilot trial of injectable, extended-release naltrexone for the treatment of co-occurring cocaine and alcohol dependence.

Pettinati HM, Kampman KM, Lynch KG, Dundon WD, Mahoney EM, Wierzbicki MR, O'Brien CP.

Am J Addict. 2014 Nov-Dec;23(6):591-7. doi: 10.1111/j.1521-0391.2014.12146.x. Epub 2014 Sep 22.

PMID:
25251201
43.

Moving internet gaming disorder forward: A reply.

Petry NM, Rehbein F, Gentile DA, Lemmens JS, Rumpf HJ, Mößle T, Bischof G, Tao R, Fung DS, Borges G, Auriacombe M, GonzálezIbáñez A, Tam P, O'Brien CP.

Addiction. 2014 Sep;109(9):1412-3. doi: 10.1111/add.12653. No abstract available.

PMID:
25103100
44.

Internet gaming and addiction: a reply to King & Delfabbro.

Petry NM, Rehbein F, Gentile DA, Lemmens JS, Rumpf HJ, Mößle T, Bischof G, Tao R, Fung DS, Borges G, Auriacombe M, GonzálezIbáñez A, Tam P, O'Brien CP.

Addiction. 2014 Sep;109(9):1567-8. doi: 10.1111/add.12549. Epub 2014 Apr 14. No abstract available.

PMID:
24724947
45.

Nipping cue reactivity in the bud: baclofen prevents limbic activation elicited by subliminal drug cues.

Young KA, Franklin TR, Roberts DC, Jagannathan K, Suh JJ, Wetherill RR, Wang Z, Kampman KM, O'Brien CP, Childress AR.

J Neurosci. 2014 Apr 2;34(14):5038-43. doi: 10.1523/JNEUROSCI.4977-13.2014.

46.

Managing patients with a history of substance abuse.

O'Brien CP.

Can Fam Physician. 2014 Mar;60(3):248-50. No abstract available.

47.

Molecular testing in oncology: problems, pitfalls and progress.

O'Brien CP, Taylor SE, O'Leary JJ, Finn SP.

Lung Cancer. 2014 Mar;83(3):309-15. doi: 10.1016/j.lungcan.2013.12.010. Epub 2014 Jan 3. Review.

PMID:
24472389
48.

An international consensus for assessing internet gaming disorder using the new DSM-5 approach.

Petry NM, Rehbein F, Gentile DA, Lemmens JS, Rumpf HJ, Mößle T, Bischof G, Tao R, Fung DS, Borges G, Auriacombe M, González Ibáñez A, Tam P, O'Brien CP.

Addiction. 2014 Sep;109(9):1399-406. doi: 10.1111/add.12457. Epub 2014 Jan 23.

PMID:
24456155
49.

Conversation with Charles P. O'Brien.

O'Brien CP.

Addiction. 2014 Apr;109(4):530-7. doi: 10.1111/add.12318. Epub 2014 Jan 17. No abstract available.

PMID:
24433275
50.

Application of statistical process control to qualitative molecular diagnostic assays.

O'Brien CP, Finn SP.

Front Mol Biosci. 2014 Nov 5;1:18. doi: 10.3389/fmolb.2014.00018. eCollection 2014.

Supplemental Content

Loading ...
Support Center